Epix Pegs Vasovist Approval In Second Half 2007 Following Second “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s action letter for the vascular imaging agent requires an additional clinical trial and a re-read of images from previous trials.